| 1. |
Clinical practice guidelines for the management of dyslipidaemias among renal transplant recipients have been released |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 451,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Olopatadine improves symptoms, QOL in seasonal allergic rhinitis |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 451,
2004,
Page 3-4
&NA;,
Preview
|
|
摘要:
Recent epidemiological studies show that the prevalence of seasonal allergic rhinitis is increasing worldwide, and currently affects > 40% of paediatric individuals and 10%−30% of adults in the US alone. Symptoms include sneezing, watery nasal discharge and nasal obstruction, with severity ranging from mild to extremely debilitating. The impact of allergic rhinitis on health extends to predisposition of patients to comorbid asthma, sinusitis, conjunctivitis and otitis media with effusion. Poorly controlled allergic rhinitis may also cause sleep disturbances, and lead to learning problems among paediatric individuals. Thus, effective treatments are of great importance for controlling the symptoms of allergic rhinitis and positively influencing patients' QOL. Olopatadine is a second-generation antihistamine and mast cell stabiliser, which is marketed for the treatment of allergic rhinitis, allergic conjunctivitis, pruritus and urticaria. The efficacy of olopatadine for treating seasonal allergic rhinitis, and its effect on patients' QOL, were examined in several studies presented at a poster session at the 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology [San Francisco, US; March 2004].
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Healthcare providers urged to respond to musculoskeletal pain burden |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 451,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
US Medicare health plans' performances differ |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 451,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Patient-controlled esomeprazole justified in GERD |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 451,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Simple flow chart cost cutting for surgery recipients |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 451,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Variation in opioid use suggests room for improvement |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 451,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Spinal cord stimulation (SCS) offers economic benefits for the treatment of chronic pain by paying for itself in less than 2.5 years, |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 451,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Home antibacterial therapy preserves QOL, saves costs |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 451,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Sales of omalizumab [Xolair] have been predicted to reach $US3.3 billion in 2012 |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 451,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
